Weight Management in Ireland - New Report Available
Weight management in Ireland increased in current value by 2% in 2013, with growth compromised by the poor performance of OTC obesity due to the withdrawal of GlaxoSmithKline (Ireland) Ltd's product Alli. Alli and OTC obesity in general suffered significantly in 2012 as a result of the brand's supply problems, which lasted for the majority of the year and led to OTC obesity declining in current value by 72% in 2012. 2013 saw little respite, with value sales of OTC...
View full press release